The study identifies an immunodominant neutralization site involving residues of VP3 and VP1, and a second potentially independent site involving residue 221 of VP1 in the hepatitis A virus.
No takes yet. Share an insight, caveat, or question.
May guide HAV vaccine epitope targeting; leaves open human validation and clinical relevance.
Liu et al. (1992) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: